Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | TRPC5 | Q9UL62 | 7/20 | 0.50 |
| ▸ | TIPARP | Q7Z3E1 | 6/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | HTR7 | P34969 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | HTR3A | P46098 | 1/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20818389 | 0.72 | TRPC5 (0.73) | POLBALDH1A1TRPC5 | |
| SCHEMBL25616990 | 0.71 | POLB (0.65) | POLBALDH1A1TRPC5TIPARPHTR1A | |
| SCHEMBL20831509 | 0.71 | TRPC5 (0.54) | ALDH1A1TRPC5HTR1AHTR7 | |
| SCHEMBL31244613 | 0.71 | POLB (0.55) | POLBALDH1A1TRPC5TIPARPHTR1A | |
| SCHEMBL31244746 | 0.71 | TIPARP (0.65) | POLBALDH1A1TRPC5TIPARPHTR1A | |
| SCHEMBL24763742 | 0.71 | TIPARP (0.59) | POLBALDH1A1TRPC5TIPARP | |
| SCHEMBL31244835 | 0.71 | POLB (0.55) | POLBALDH1A1TRPC5TIPARPHTR1A | |
| SCHEMBL20818713 | 0.69 | TRPC5 (0.80) | ALDH1A1TRPC5 | |
| SCHEMBL17586677 | 0.68 | POLB (0.40) | POLBALDH1A1TRPC5TIPARP | |
| SCHEMBL31244680 | 0.68 | POLB (0.51) | POLBALDH1A1TRPC5TIPARP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240336629-A1 | Tricyclic Derivatives Useful As PARP7 Inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-10-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240336629-A1 | Tricyclic Derivatives Useful As PARP7 Inhibitors | PARP1, PARP2, PARP11 | POLB 38/4885ALDH1A1 1842/4885TRPC5 3665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.